source
- Intellia reports positive Phase 3 readout for CRISPR gene-editing therapy in hereditary angioedemaIntellia Therapeutics announced that its CRISPR-based therapy achieved a successful readout in a Phase 3 trial for hereditary angioedema, a rare condition marked by sudden, potentially dangerous sw…
- New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warnA new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…